Kite, a Gilead Company, has announced a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology firm, for $350 million. Interius is known for its development of in vivo CAR therapeutics. The acquisition is set to enhance Kite's cell therapy capabilities by integrating Interius's in vivo platform, which allows the generation of CAR T-cells directly within a patient's body. This innovative approach could potentially streamline treatment processes by eliminating the need for cell harvesting and reinfusion associated with traditional therapies. Interius's team will join Kite's research operations, forming a center of excellence in Philadelphia to expedite the development of next-generation in vivo therapies.